$RGNT

REGENTIS BIOMATERIALS LTD.

CIK:0001912966|SEC Filings

Statements of Comprehensive Income (Loss) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Research and development expenses, net:
Horizon 2020 grant		$ 2,306
Research and development expenses	(331)	(662)	(806)
Research and development expenses, net	(331)	1,644	(806)
General and administrative expenses	(6,637)	(712)	(1,125)
Operating profit (loss)	(6,968)	932	(1,931)
Financial income (expense), net:
Change in fair value of convertible notes	(4,936)	3,483	(2,019)
Changes in fair value of warrant liability	160	463	62
Other financing expense, net	(1,904)	(77)	(244)
Financial income (expense), net	(6,680)	3,869	(2,201)
Net income (loss) and comprehensive income (loss)	$ (13,648)	$ 4,801	$ (4,132)
Basic net income (loss) per share	$ (24.16)	$ 1.72	$ (24.09)
Dilutednet income (loss) per share	$ (24.16)	$ 1.72	$ (24.09)
Weighted average number of ordinary shares used in computing basic	566,744	2,765,850	173,508
Weighted average number of ordinary shares used in computing diluted	566,744	2,765,850	173,508

Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
Statements of Cash Flows - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities
Net income (loss)	$ (13,648)	$ 4,801	$ (4,132)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Change in fair value of convertible notes	4,936	(3,483)	2,019
Share based payment	7,042
Exchange rate differences on grant liability		(68)	73
Change in fair value of warrant liability	(160)	(463)	(62)
Amortization of the discount on short-term loans	245	161	173
Interest expense on short-term loans	79	10
Changes in assets and liabilities:
Other current assets	(163)	(238)	462
Trade accounts payable	14	(101)	147
Other accounts payable	280	(1,260)	100
Net cash used in operating activities	(1,375)	(641)	(1,220)
Cash flows from financing activities
Issuance of ordinary shares and warrants in an initial public offering, net (see Note 11)	8,224
Repayment of short-term loan		(325)
Proceeds from issuance of convertible notes		450
Proceeds from short-term loans	300	400	325
Net cash provided by financing activities	8,524	525	325
Net change in cash and cash equivalents	7,149	(116)	(895)
Cash and cash equivalents at the beginning of the year	229	345	1,240
Cash and cash equivalents at the end of the year	7,378	229	345
Non-cash financing activities:
Conversion of convertible notes into ordinary shares	9,308		1,086
Conversion of accrued payroll salary into short-term loan (see Note 5)		$ 117

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 7,378	$ 229
Other current assets	240	253
Total assets	7,618	482
Current liabilities:
Trade accounts payable	266	252
Other accounts payable	1,411	1,131
Short-term loans	1,197	573
Convertible notes		4,372
Warrant liability		160
Total current liabilities	2,874	6,488
Total liabilities	2,874	6,488
Commitments and contingencies
Temporary equity:
Total temporary equity		35,098
Shareholders’ equity (deficit):
Ordinary shares, no par value; Authorized: 19,677,478 shares; Issued and outstanding: 5,179,378 and 162,198 shares as of December 31, 2025 and 2024 respectively
Additional paid-in capital	60,538	1,042
Accumulated deficit	(55,794)	(42,146)
Total shareholders’ equity (deficit)	4,744	(41,104)
Total liabilities, temporary equity and shareholders’ equity (deficit)	7,618	482
Convertible Preferred A Shares
Temporary equity:
Total temporary equity		598
Convertible Preferred B Shares
Temporary equity:
Total temporary equity		7,575
Convertible Preferred C Shares
Temporary equity:
Total temporary equity		10,616
Convertible Preferred D-1 Shares
Temporary equity:
Total temporary equity		12,500
Convertible Preferred D-2 Shares
Temporary equity:
Total temporary equity		$ 3,809